193 Longitudinal tau PET and atrophy individuals, irrespective of their baseline amyloid status and that cortical thickness decreases over time in Aβ+ individuals only. On group level no change in rCBF over the two-year follow-up period was observed, but both in- and decreases were found on individual level. This stresses the need for future longitudinal studies into complex longitudinal changes in rCBF and their association with (changes in) tau pathology. Furthermore, higher tau pathology at baseline was associated with faster cortical thinning over time in Aβ+ individuals. These results support disease models in which tau pathology is a driver of neurodegenerative processes, which will further contribute to potentially establishing the utility of (a single) tau PET as a predictive tool in terms of identifying slow- or fast-degenerating individuals, which may in turn be important for selection criteria in clinical trials. 7
RkJQdWJsaXNoZXIy MjY0ODMw